browse Browse

pac.dog pac.dog / Lobbying

1st Quarter - Report · 2026

Filing UUID
ab816a2a-3706-48a0-9219-dad0ea8e4f18
Type
Q1 — 1st Quarter - Report
Period
first_quarter
Year
2026
Posted
2026-04-20 00:53:33
Income (reported)
$50,000
Expenses (reported)
Filing document
Open on lda.senate.gov
Registrant (lobbying firm)

CROSSROADS STRATEGIES, LLC

lobbying firm

Contact
MATHEW LAPINSKI
Phone
+1 202-559-0170
Address
zip:20002, city:Washington, state:DC, street:800 North Capitol Street, NW, Suite 800
Client

PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA

represents biopharmaceutical research companies

State
DC
Country
US
Government-entity client
false
Effective date
2017-03-01
Issues lobbied + lobbyists (4)

HCR — Health Issues

340B drug discount program; drug pricing; importation of biopharmaceuticals; direct-to-consumer (DTC) advertising; transparency; international pharmaceutical supply chain; PBM reform; TRICARE Pharmacy Program (FY2027 National Defense Authorization Act); Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; S.891, Bipartisan Health Care Act; S.527, Prescription Pricing for the People Act of 2025; S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act; S.1097, Interagency Patent Coordination and Improvement Act of 2025; S.1095, Stop STALLING Act; S.1096, Preserve Access to Affordable Generics and Biosimilars Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients; FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; FY2027 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations.

Lobbyists:

Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE

MMM — Medicare/Medicaid

General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; noninterference; CMMI Drug Pricing Demonstration Programs; drug pricing; Valued-Based Payments; H.R.1492/S.832, EPIC Act of 2025; Inflation Reduction Act of 2022 (P.L.117-169) implementation.

Lobbyists:

Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE

pac.dog is a free, independent, non-partisan research tool. Every candidate, committee, bill, vote, member, and nonprofit on this site is mirrored from primary U.S. government sources (FEC, congress.gov, govinfo.gov, IRS) and each state's Secretary of State / election commission — no third-party data vendors, no paywall, no editorial intermediation. Citations to the originating source are on every detail page.